Wu Yiling, the billionaire founding father of conventional Chinese language medication producer Shijiazhuang Yiling Pharmaceutical, noticed his wealth plunge by $1.1 billion in simply in the future amid questions over the efficacy of his purported Covid-treatment medicine.
The 72-year-old is going through rising skepticism of Yiling’s signature product, a natural treatment known as Lianhua Qingwen. Shares of the Shenzhen-listed firm had nearly quadrupled because the begin of the pandemic in 2020, as capsules of Lianhua Qingwen had been recommended by Chinese language government authorities and well being specialists for treating delicate Covid instances.
However the rally now seems to have come to an finish. The corporate’s inventory plunged by its day by day buying and selling restrict of 10% in Shenzhen on Monday—dragging Wu’s wealth all the way down to $4.7 billion from $5.8 billion on the World’s Actual-Time Billionaires’ Record. The drop got here after Wang Sicong, the outspoken son of Wang Jianlin, the chairman of Dalian Wanda, reposted late final week a video on his verified account on Sina Weibo that questioned whether or not the World Well being Group (WHO) has ever really useful Lianhua Qingwen as a Covid therapy.
What’s extra, Chinese language healthcare platform Dingxiang Doctor can also be now advising towards utilizing the capsules, that are constituted of components that embody honeysuckle, liquorice root and apricot seed. In an article printed at midnight on Sunday, the platform wrote that there’s at present no proof suggesting that Lianhua Qingwen can forestall Covid infections.
A Yiling consultant acknowledged over the cellphone a request for remark, however the firm was unable to supply a response. In a submitting to the Shenzhen Inventory Change, the corporate stated Lianhua Qingwen accounted for 42% of its 3.4 billion yuan ($529 million) in gross sales within the first three quarters of 2021 (Yiling additionally makes natural therapies for cardiovascular and tumor-related ailments). In early April, the corporate donated $7.9 million value of Lianhua Qingwen capsules to Shanghai, which had been distributed to residents because the day by day rely of confirmed Covid instances continues to mount.
China, within the meantime, has additionally been attempting to advertise Lianhua Qingwen overseas–and the outcomes have to this point been combined. Russia started to allow the sale of the capsules in late 2020, whereas authorities elsewhere, equivalent to these within the U.S. and Singapore, have questioned the efficacy of the capsules for treating Covid. In the meantime, the WHO has not accepted or really useful Lianhua Qingwen as a Covid therapy.